SUBSCRIBERS

GSK opens S$130m facilities in Jurong

New plant and expanded building will step up pharmaceutical firm's output of active ingredients in its HIV medication

Published Fri, Jul 5, 2019 · 09:50 PM

Singapore

PHARMACEUTICAL giant GlaxoSmithKline (GSK) unveiled a new, fully automated continuous manufacturing facility and an expanded production building at its Jurong site on Friday, worth a total of S$130 million.

The site upgrades will accelerate GSK's global supply chain and, in particular, its production of active pharmaceutical ingredients (APIs) such as Dolutegravir and Lamivudine, key assets in GSK's HIV medication.